Libroxar

Buprenorphine, the active ingredient in Libroxar, is a partial opioid agonist combined with naloxone, an opioid antagonist, presented as a sublingual formulation for sublingual use. It is indicated for the treatment of opioid dependence and for maintenance therapy in patients with opioid use disorder.

GNH USA supplies Libroxar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for regulated medicines. Customers benefit from comprehensive regulatory support and timely delivery across multiple regions.

Libroxar, a buprenorphine/naloxone combination, is used within the opioid dependence treatment pathway to manage opioid use disorder.

- Opioid dependence: reduces cravings and withdrawal symptoms, supporting long‑term abstinence and facilitating psychosocial rehabilitation. - Opioid use disorder maintenance therapy: provides stable μ‑opioid receptor activation to prevent relapse while minimizing euphoric effects. - Opioid withdrawal management: alleviates acute withdrawal signs during the induction phase, allowing a smoother transition to maintenance dosing.

Libroxar may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may resolve with continued therapy. - Headache: transient cranial pain often improving over time. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Sweating: increased perspiration, especially during early treatment.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening, requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure, potentially causing dizziness or fainting. - Hepatotoxicity: liver enzyme elevations or injury, monitored through laboratory tests.

When prescribing Libroxar, clinicians should consider several precautionary measures to ensure safe use.

- Assess opioid dependence severity: evaluate patient history and current opioid use before initiating therapy. - Monitor for respiratory function: observe breathing, especially during dose adjustments or when combined with CNS depressants. - Avoid use in acute severe asthma: risk of bronchospasm may be heightened. - Counsel on misuse potential: educate patients about the naloxone component and the importance of sublingual administration only. - Pregnancy and lactation: weigh benefits against risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Libroxar can interact with other medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - Benzodiazepines: combined CNS depression may cause profound respiratory depression. - Alcohol: additive sedative effects increase risk of overdose. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise buprenorphine levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Opioid analgesics: may diminish naloxone’s deterrent effect and increase opioid load. - CNS depressants (e.g., gabapentin, pregabalin): monitor for enhanced sedation. - Rifampin: induces metabolism, potentially reducing buprenorphine efficacy.